Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer
J. Datta, N. Willingham, J. Manouchehri, P. Schnell, M. Sheth, J. J. David, M. Kassem, T. A. Wilson, H. S. Radomska, C. C. Coss, C. E. Bennett, R. K. Ganju, S. D. Sardesai, M. Lustberg, B. Ramaswamy, , M. A. Cherian
This study shows that selective ERβ agonists reduce viability of ER+ breast cancer cells and suggest their potential as a therapeutic strategy when combined with ER blockade.
bioRxiv · Jan 14, 2022Cancer Biology